TELEHEALTH TECHNOLOGIES DEVELOPMENT (SBIR/STTR)
RELEASE DATE: November 18, 2002
PA NUMBER: PA-03-030
EXPIRATION DATE: January 1, 2004 unless reissued.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
(http://www.nibib.nih.gov)
THIS PA CONTAINS THE FOLLOWING INFORMATION
o Purpose of the PA
o Research Objectives
o Mechanism(s) of Support
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Where to Send Inquiries
o Submitting an Application
o Peer Review Process
o Review Criteria
o Award Criteria
o Required Federal Citations
PURPOSE OF THIS PA
The National Institute of Biomedical Imaging and Bioengineering (NIBIB)
invites grant applications for Small Business Innovation Research (SBIR) and
Small Business Technology Transfer (STTR) awards to support design and
development of novel telehealth instrumentation or technologies that can be
applied to a broad spectrum of disorders and diseases. There is also a
parallel Request for Applications (RFA) announcement on this topic RFA-EB-03-
005 (https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-03-005.html).
Telehealth is defined by the Federal Communications Commission and by the
DHHS Office of Health Promotion and Disease Prevention as "the use of
communications technologies to provide and support health care at a distance.
Examples include the use of communications to provide patient treatment,
often via still images or video, and the exchange and distribution of public
health information." Issues amenable to technical solution arise in the
diagnosis, treatment, and follow-up with a patient at a distance. The
technical feasibility of telehealth applications has been well demonstrated
for several specific applications in the past. The current need is to
generalize remote access technology to be adaptable to a broad range of
telehealth applications, to develop mechanisms in which the technology can be
integrated seamlessly into the routine of the provider and the patient, and
to develop technology for standardizing and incorporating state-of-the-art
security protocols for verifying user identities and preserving patient
confidentiality.
This Program Announcement (PA) is intended to support an integrated approach
on the part of biomedical engineers or imaging scientists with medical care
professionals.
RESEARCH OBJECTIVES
The main objective of broadening the usability issues in telehealth cover but
are not limited to the following application areas:
One type of telehealth, store and forward, involves image-based consults,
where medical diagnosis or treatment of a patient in a remote clinical care
setting is accomplished through the forwarding of the locally-obtained
medical images to the pertinent specialist. Examples include teleradiology,
telepathology, and teledermatology. To facilitate this practice, there is a
need for specialized hardware and software for image compression, storage,
transmission, and display. The research objective is the development and
validation of the specialized hardware or software. In addition, the quality
of the workstation monitors at the receiving end is important. In this case,
the research objective can range from the determination of quantitative
measures of the necessary workstation image quality, or technical
improvements in workstation monitors.
For real-time but not necessarily image-based examinations with a distant
health-care consultant, additional considerations come in to play. The
research objective is to design and develop the needed easy-to-use peripheral
devices that can aid in a remote interactive examination.
Another type of telehealth takes place in a non-clinical setting. Home-based
health care using physiological monitoring devices would benefit from
development of low-cost, low-power biosensors, wireless technologies, and
inexpensive interactive video for pre-operative or follow-up interactions
with a health care provider.
In mass casualty situations on-the-scene health professionals could do with
hand-held or portable digital imaging and display devices. Additional areas
in need of development are wearable patient monitors, which are lightweight
and non-invasive, long-life batteries, and telemetry hardware and software.
The application should make clear that the proposed research is
scientifically sound, the qualifications of the investigators are
appropriate, and the resources available to the investigators are adequate.
Applications from groups interested in developing suitable novel approaches
are encouraged. It is expected that this research will require expertise
from a variety of disciplines, including engineering, computer science,
physics, mathematics, and medicine.
MECHANISM OF SUPPORT
This PA will use the NIH Small Business Innovation Research (SBIR) and Small
Business Technology Transfer (STTR) award mechanisms. As an applicant, you
will be solely responsible for planning, directing, and executing the
proposed project.
Applications can be submitted for support as Phase I STTR (R41) or Phase I
SBIR (R43) grants; Phase II STTR (R42) or Phase II SBIR (R44)grants; or under
the SBIR/STTR FAST-TRACK option as described in the SBIR/STTR Omnibus
Solicitation. Phase II applications in response to this PA will only be
accepted as competing continuations of previously funded NIH Phase I SBIR/STTR
awards. The Phase II proposal must be a logical extension of the Phase I
research.
Information on the FAST-TRACK process and the SBIR/STTR Omnibus Solicitation
is available at https://grants.nih.gov/grants/funding/sbir.htm.
ELIGIBILITY REQUIREMENTS
Eligibility requirements are described in the SBIR/STTR Omnibus Solicitation.
Any small business concern, independently owned and operated by United States
citizens or lawfully admitted permanent resident aliens, which is located in
the United States, has 500 or fewer employees and is organized for profit, may
apply.
INDIVIDUALS ELIGIBLE TO BECOME PRINCIPAL INVESTIGATORS
Any individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented racial
and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH programs.
WHERE TO SEND INQUIRIES
We encourage inquiries concerning this PA and welcome the opportunity to
answer questions from potential applicants. Inquiries may fall into three
areas: scientific/research and financial or grants management issues:
o Direct your questions about scientific/research issues to:
Mary S Pastel, ScD
Division of Biomedical Imaging
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health/DHHS
Democracy Two, Suite 200
Bethesda, MD 20892-5469
Telephone: (301) 451-4781
Email: pastelm@mail.nih.gov
o Direct your questions about financial or grants management matters to:
Mr. Nick Mitrano
Grants Management Specialist
National Institute of Biomedical Imaging and Bioengineering
National Institutes of Health/DHHS
Democracy Two, Suite 900
Bethesda, MD 20892-5469
Telephone: (301) 451-4782
Email: mitranni@mail.nih.gov
SUBMITTING AN APPLICATION
Detailed information regarding submitting SBIR grant applications is available
on the NIH website at
https://grants.nih.gov/grants/funding/sbirsttr1/index.pdf
SBIR/STTR applicants must use the PHS 398 instructions and forms for all Phase
I and Phase II applications. See https://grants.nih.gov/grants/forms.htm for
links to the PHS 398 Application Instructions and new Fillable Forms.
IMPORTANT NOTE: Applicants should refer to Chapter VI
https://grants.nih.gov/grants/funding/phs398/instructions2/
p1_preparing_SBIR_STTR_app.htm of the PHS 398
instructions (https://grants.nih.gov/grants/funding/phs398/phs398.html)prior to
preparing an SBIR or STTR application. Please note that Phase I applications
with budgets of $100,000 or less total costs should use the Modular Budget
Page and omit Form Pages 4 and 5. See
https://grants.nih.gov/grants/funding/phs398/instructions2/
p1_SBIRSTTR_general_instructions.htm. For
answers to frequently asked questions about using the new fillable forms, see
FAQs: Revised PHS 398 and PHS 2590 Forms and Instructions at
https://grants.nih.gov/grants/forms_faq.pdf.
For further assistance contact GrantsInfo, Telephone (301) 710-0267,
Email:GrantsInfo@nih.gov.
SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of
the application, including the checklist, and five signed photocopies, in one
package to:
Center For Scientific Review
National Institutes Of Health
6701 Rockledge Drive, Room 1040, MSC 7710
Bethesda, MD 20892-7710
Bethesda, MD 20817 (for express/courier service)
APPLICATION PROCESSING: Applications must be received by or mailed on or
before the receipt dates described at
https://grants.nih.gov/grants/funding/submissionschedule.htm. If an
application is received after that date, it will be returned to the applicant
without review.
The Center for Scientific Review (CSR) will not accept any application in
response to this PA that is essentially the same as one currently pending
initial review, unless the applicant withdraws the pending application. The
CSR will not accept any application that is essentially the same as one
already reviewed. This does not preclude the submission of substantial
revisions of applications already reviewed, but such applications must
include an Introduction addressing the previous critique.
Please Note: As of November 27, 2001, all applications and other deliveries
to the Center for Scientific Review must come via courier delivery or the
USPS. Applications delivered by individuals to the Center for Scientific
Review will no longer be accepted. For additional information, see the NIH
Guide Notice
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-012.html.
REVIEW CONSIDERATIONS
Upon receipt, applications will be reviewed for completeness and
responsiveness by the CSR. Incomplete and/or non-responsive applications
will be returned to the applicant without further consideration.
Applications that are complete and responsive to the PA will be evaluated for
scientific and technical merit by an appropriate peer review group convened
by the CSR in accordance with the review criteria stated below. As part of
the initial merit review, all applications will:
o Receive a written critique
o Undergo a process in which only those applications deemed to have the
highest scientific merit, generally the top half of the applications under
review, will be discussed and assigned a priority score
o Receive a second level review by the National Advisory Council for
Biomedical Imaging and Bioengineering.
REVIEW CRITERIA
The goals of NIH-supported research are to advance our understanding of
biological systems, improve the control of disease, and enhance health. In
the written comments, reviewers will be asked to discuss the following
aspects of your application in order to judge the likelihood that the
proposed research will have a substantial impact on the pursuit of these
goals:
o Significance
o Approach
o Innovation
o Investigator
o Environment
The scientific review group will address and consider each of these criteria
in assigning your application's overall score, weighting them as appropriate
for each application. Your application does not need to be strong in all
categories to be judged likely to have major scientific impact and thus
deserve a high priority score. For example, you may propose to carry out
important work that by its nature is not innovative but is essential to move
a field forward.
(1) SIGNIFICANCE: Does the proposed project have commercial potential to
lead to a marketable product or process? Does this study address an important
problem? What may be the anticipated commercial and societal benefits of the
proposed activity? If the aims of the application are achieved, how will
scientific knowledge be advanced? Does the proposal lead to enabling
technologies (e.g., instrumentation, software) for further discoveries?
Will the technology have a competitive advantage over existing/alternate
technologies that can meet the market needs?
(2) APPROACH: Are the conceptual framework, design, methods, and analyses
adequately developed, well integrated, and appropriate to the aims of the
project? Is the proposed plan a sound approach for establishing technical
and commercial feasibility? Do you acknowledge potential problem areas and
consider alternative tactics? Are the milestones and evaluation procedures
appropriate?
(3) INNOVATION: Does your project challenge existing paradigms or employ
novel technologies, approaches or methodologies? Are the aims original and
innovative?
(4) INVESTIGATOR: Is the Principal Investigator capable of coordinating and
managing the proposed SBIR/STTR? Is the work proposed appropriate to the
experience level of the Principal Investigator and other researchers,
including consultants and subcontractors(if any)? Are the relationships of
the key personnel to the small business and to other institutions appropriate
for the work proposed?
(5) ENVIRONMENT: Is there sufficient access to resources (e.g., equipment,
facilities)? Does the scientific and technological environment in which your
work will be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific environment
or employ useful collaborative arrangements?
In accordance with NIH policy, all applications will also be reviewed with
respect to the following:
o PROTECTIONS: The adequacy of the proposed protection for humans, animals,
or the environment, to the extent they may be adversely affected by the
project proposed in the application.
o INCLUSION: The adequacy of plans to include subjects from both genders,
all racial and ethnic groups (and subgroups), and children as appropriate for
the scientific goals of the research. Plans for the recruitment and
retention of subjects will also be evaluated. (See Inclusion Criteria
included in the section on Federal Citations, below)
o BUDGET: The reasonableness of the proposed budget and the requested period
of support in relation to the proposed research.
Phase II Applications
In addition to the above criteria, to what degree was progress toward the
Phase I objectives met and feasibility demonstrated in providing a solid
foundation for the proposed Phase II activity?
Phase I/Phase II Fast-Track Applications
For Phase I/Phase II Fast-Track applications, the following additional
criteria will be applied: Does the Phase I application specify clear,
measurable goals (milestones) that should be achieved prior to initiating
Phase II? Did the applicant submit a concise Product Development Plan that
adequately addresses the areas described in the Omnibus Solicitation? To what
extent was the applicant able to obtain letters of interest, additional
funding commitments, and/or resources from the private sector or non-SBIR/STTR
funding sources that would enhance the likelihood for commercialization?
The Phase I application should specify clear, measurable goals (milestones)
that should be achieved prior to initiating Phase II. Failure to provide
clear, measurable goals may be sufficient reason for the study section to
judge the application non-competitive.
AWARD CRITERIA
Applications will compete for available funds with all other recommended SBIR
and STTR applications. Funding decisions for Phase I or Phase II applications
will be based on quality of the proposed project as determined by peer review,
availability of funds, and relevance to program priorities.
FAST-TRACK Phase II applications may be funded following submission of the
Phase I progress report and other documents necessary for continuation. Phase
II applications will be selected for funding based on the initial priority
score, NIBIB's assessment of the Phase I progress and determination that Phase
I goals were achieved, the project's potential for commercial success, and the
availability of funds.
REQUIRED FEDERAL CITATIONS
INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH: It is the policy of
the NIH that women and members of minority groups and their sub-populations
must be included in all NIH-supported clinical research projects unless a
clear and compelling justification is provided indicating that inclusion is
inappropriate with respect to the health of the subjects or the purpose of the
research. This policy results from the NIH Revitalization Act of 1993 (Section
492B of Public Law 103-43).
All investigators proposing clinical research should read the AMENDMENT "NIH
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical
Research - Amended, October, 2001," published in the NIH Guide for Grants and
Contracts on October 9, 2001
(https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html);
a complete copy of the updated Guidelines are available at
https://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm.
The amended policy incorporates: the use of an NIH definition of clinical
research; updated racial and ethnic categories in compliance with the new OMB
standards; clarification of language governing NIH-defined Phase III clinical
trials consistent with the new PHS Form 398; and updated roles and
responsibilities of NIH staff and the extramural community. The policy
continues to require for all NIH-defined Phase III clinical trials that: a)
all applications or proposals and/or protocols must provide a description of
plans to conduct analyses, as appropriate, to address differences by
sex/gender and/or racial/ethnic groups, including subgroups if applicable;
and b) investigators must report annual accrual and progress in conducting
analyses, as appropriate, by sex/gender and/or racial/ethnic group
differences.
INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS:
The NIH maintains a policy that children (i.e., individuals under the age of
21) must be included in all human subjects research, conducted or supported
by the NIH, unless there are scientific and ethical reasons not to include
them. This policy applies to all initial (Type 1) applications submitted for
receipt dates after October 1, 1998.
All investigators proposing research involving human subjects should read the
"NIH Policy and Guidelines" on the inclusion of children as participants in
research involving human subjects that is available at
https://grants.nih.gov/grants/funding/children/children.htm.
REQUIRED EDUCATION ON THE PROTECTION OF HUMAN SUBJECT PARTICIPANTS: NIH policy
requires education on the protection of human subject participants for all
investigators submitting NIH proposals for research involving human subjects.
You will find this policy announcement in the NIH Guide for Grants and
Contracts Announcement, dated June 5, 2000, at
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.
PUBLIC ACCESS TO RESEARCH DATA THROUGH THE FREEDOM OF INFORMATION ACT: The
Office of Management and Budget (OMB) Circular A-110 has been revised to
provide public access to research data through the Freedom of Information Act
(FOIA) under some circumstances. Data that are (1) first produced in a
project that is supported in whole or in part with Federal funds and (2) cited
publicly and officially by a Federal agency in support of an action that has
the force and effect of law (i.e., a regulation) may be accessed through FOIA.
It is important for applicants to understand the basic scope of this
amendment. NIH has provided guidance at
https://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.
Applicants may wish to place data collected under this PA in a public
archive, which can provide protections for the data and manage the
distribution for an indefinite period of time. If so, the application should
include a description of the archiving plan in the study design and include
information about this in the budget justification section of the
application. In addition, applicants should think about how to structure
informed consent statements and other human subjects procedures given the
potential for wider use of data collected under this award.
URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals
for NIH funding must be self-contained within specified page limitations.
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs)
should not be used to provide information necessary to the review because
reviewers are under no obligation to view the Internet sites. Furthermore,
we caution reviewers that their anonymity may be compromised when they
directly access an Internet site.
HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving
the health promotion and disease prevention objectives of "Healthy People
2010," a PHS-led national activity for setting priority areas. This PAR is
related to one or more of the priority areas. Potential applicants may obtain
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.
AUTHORITY AND REGULATIONS: This program is described in the Catalog of
Federal Domestic Assistance No. 93.286 and 93.287 and is not subject to the
intergovernmental review requirements of Executive Order 12372 or Health
Systems Agency review. Awards are made under authorization of Sections 301
and 405 of the Public Health Service Act as amended (42 USC 241 and 284)and
administered under NIH grants policies described at
https://grants.nih.gov/grants/policy/policy.htm and under Federal Regulations
42 CFR 52 and 45 CFR Parts 74 and 92.
The PHS strongly encourages all grant recipients to provide a smoke-free
workplace and discourage the use of all tobacco products. In addition,
Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in
certain facilities (or in some cases, any portion of a facility) in which
regular or routine education, library, day care, health care, or early
childhood development services are provided to children. This is consistent
with the PHS mission to protect and advance the physical and mental health of
the American people.